Trial Information

Summary: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1

Status: No longer recruiting

Protocol Number: ML17908

Sponsor: Roche Products Pty Ltd

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of induction dosing with PEGASYS and ribavirin on sustained virological response in patients with chronic hepatitis C viral infection, genotype-1

Brief Summary: This study will evaluate the addition of a higher-dose induction treatment period with PEGASYS and ribavirin prior to standard-dose treatment with PEGASYS and ribavirin, compared to standard dose treatment without induction dosing, in treatment-naive patients with CHC, genotype-1. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals. Target sample size is 816.

Study Phase: IV

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Parallel
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Hepatitis C, Chronic

Intervention Type: Drug

Intervention Name: peginterferon alfa-2a (40KD)[PEGASYS]

Primary Outcome: 1. Efficacy: Sustained virologic response rate at 24 weeks post-completion of the 48-week treatment period

Key Secondary Outcomes: 1. Efficacy: Sustained biochemical and combined sustained biochemical and virologic response rate, percent of patients with non-detectable HCV-RNA and/or 2-log drop in HCV-RNA up to Week 48. Safety: AEs

Inclusion Criteria:

  • adult patients 18-75 years of age;
  • chronic CHC infection, genotype-1;
  • chronic liver disease consistent with CHC infection (must meet Australian section 100 criteria);
  • compensated liver disease;
  • naive to therapy for CHC infection (ie, no previous treatment with an interferon or an interferon plus ribavirin).

Exclusion Criteria:

  • systemic anti-viral, anti-neoplastic, or immunomodulatory treatment <=6 months before study drug;
  • co-infection with active hepatitis A or B virus, or with human immunodeficiency virus (HIV);
  • medical condition associated with chronic liver disease other than CHC infection.

Gender: Males or Females

Age Limits: Min: 18 Years Max: 75 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: September, 2004

Trial Registration Date: 08/26/2005

Date Last Updated: 04/16/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Lismore, Australia, 2480
Telephone: 973-235-5000 or 800-526-6367

  

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: May 13, 2008 at 2:40:11 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA